Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

New strategies in head and neck cancer: understanding resistance to epidermal growth factor receptor inhibitors.

Clinical cancer research : an official journal of the American Association for Cancer Research - 1 May 2010

Chen Lucy F, Cohen Ezra E W, Grandis Jennifer R

Abstract excerpt

The epidermal growth factor receptor (EGFR) is a validated target in squamous cell carcinoma of the head and neck (HNSCC). However, despite high expression of EGFR in these cancers, EGFR inhibitor monotherapy has only had modest activity. Potential mechanisms of resistance to EGFR-targeted therapies involve EGFR and Ras mutations, epithelial-mesenchymal transition, and activation of alternative and downstream...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to ErbB Receptors

Share to EGFR gene

Share to Head and Neck Neoplasms

Share to Models, Biological

Share to Mutation

Source

Open in PubMed Open full text

Identifiers

PMID: 20406834
DOI: 10.1158/1078-0432.CCR-09-2318
PMCID: PMC2887084

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

New strategies in head and neck cancer: understanding resistance to epidermal growth factor receptor inhibitors.PMID 20406834Read ↗

The quest to overcome resistance to EGFR-targeted therapies in cancer.Semantic proximity Read ↗

Emerging strategies to overcome resistance to third-generation EGFR inhibitors.Semantic proximity Read ↗

EGFR Mutations in Head and Neck Squamous Cell Carcinoma.Semantic proximity Read ↗

Application of molecular targeted therapies in the treatment of head and neck squamous cell carcinoma (Review)Semantic proximity Read ↗

Genetic alterations shaping tumor response to anti-EGFR therapies.Semantic proximity Read ↗

Cracking the EGFR code: Cancer biology, resistance mechanisms, and future therapeutic frontiers.Semantic proximity Read ↗

Molecular mechanisms of resistance to therapies targeting the epidermal growth factor receptor.Semantic proximity Read ↗

HRAS mutations and resistance to the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in head and neck squamous cell carcinoma cells.Semantic proximity Read ↗

Targeting Epidermal Growth Factor Receptor for Cancer Treatment: Abolishing Both Kinase-Dependent and Kinase-Independent Functions of the Receptor.Semantic proximity Read ↗

Therapeutic targeting of epidermal growth factor receptor in human cancer: successes and limitations.Semantic proximity Read ↗

Emerging combination therapies to overcome resistance in EGFR-driven tumors.Semantic proximity Read ↗

New Directions for Advanced Targeting Strategies of EGFR Signaling in CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.